Cowen Upgrades GenMark Diagnostics to Outperform | GenomeWeb

NEW YORK (GenomeWeb) – Cowen and Company on Friday upgraded GenMark Diagnostics to Outperform from Market Perform, lifting the company's shares for the second trading day in a row.

Cowen analyst Doug Schenkel said that recent "channel checks" suggest GenMark's ePlex molecular diagnostics system is doing well at early adopter sites in the EU, and that clinical trials for the test are likely to begin soon in the US.

"We've always liked the market opportunity, and after a long history of delays, ePlex finally appears ready to go," Schenkel wrote in a research note.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.

Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.

Researchers are using gene editing to develop more robust livestock and crops, AFP reports.

Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.